RAC has tested three other FTO inhibitors (brequinsr, FB23-2 and DAC51) on human heart cells in vitro and proved that being an FTO inhibitor isn't sufficient to be a cardio-protector (RAC announcements of 22 November 2021 and 8 December 2021).
So yes, bisantrene's cardio-protection MOA is different to.its FTO MOA. Which makes it very special.
Speculative M&A Transaction Analysis, page-735
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.90 |
Change
0.135(7.65%) |
Mkt cap ! $312.5M | |||
| Open | High | Low | Value | Volume |
| $1.78 | $1.90 | $1.78 | $407.4K | 219.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4328 | $1.89 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.91 | 1300 | 1 |
View Market Depth
| Last trade - 12.40pm 11/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |